We are committed to changing the lives of patients by applying our knowhow and innovative technologies to develop novel, value-add medicines based on real-world data and our knowledge of established products.

We have to date built a broad proprietary pipeline of 11 innovative, value-add drug candidates which we expect will all utilize the FDA’s 505(b)(2) regulatory pathway. The pipeline currently consists of a number of cardiovascular product candidates, of which the majority we intend to commercialise with our own sales force targeting a group of cardiovascular specialists and hospitals in the U.S. In addition, we are also pursuing other value-add candidates targeting other blockbuster markets.

We currently have two products on the market.

Any questions? Please contact us for all the answers you need!

If you have any enquiries about Hyloris, our mission, activities or any aspect of our company,
please click the link below to get in touch.

Contact Us